natgillin/translations-raw huggingface dataset:
Hypersensitivity after previous administration of other hepatitis B vaccines. 
Preobčutljivost po predhodnem cepljenju z drugimi cepivi proti hepatitisu B. Pri osebah s hudimi akutnimi vročinskimi boleznimi je treba cepljenje preložiti.
At month 7, GMTs were 3559.2 mIU/ml and 933.0 mIU/ml in the Fendrix and control groups who received the commercially available hepatitis B vaccine respectively, with 83.1% and 67.5% of subjects with anti-HBs antibody titres ≥100 mIU/ml respectively. 
3559,2 i.e./l, titre protiteles proti-HBs ≥100 i.e./l pa je imelo 83,1 % bolnikov.
Talk to your doctor or pharmacist before you are given Fendrix: 
Preden prejmete cepivo Fendrix, se posvetujte z zdravnikom ali farmacevtom:
Fendrix is a vaccine which prevents hepatitis B. 
Kaj je cepivo Fendrix in za kaj ga uporabljamo Fendrix je cepivo, ki se uporablja za preprečevanje hepatitisa B. Uporablja se za bolnike, ki imajo težave z ledvicami:
2adsorbed on aluminium phosphate (0.5 milligrams Al3+ in total) 3produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology 
2adsorbiran na aluminijev fosfat (skupno 0,5 miligramov Al3+)
Common (these may occur with up to 1 in 10 doses of the vaccine) 
Pogosti (pojavijo se lahko pri največ 1 na 10 odmerkov cepiva):
Uncommon (these may occur with up to 1 in 100 doses of the vaccine) 
Občasni (pojavijo se lahko pri največ 1 na 100 odmerkov cepiva):
At month 36, GMTs were 154.1 mIU/ml and 111.9 mIU/ml in the Fendrix and control groups respectively, with 58.7% and 38.5% of subjects with anti-HBs antibody titres ≥100 mIU/ml respectively. 
V 36. mesecu so bili v kontrolni skupini geometrični srednji titri 111,9 i.e./l, titre protiteles proti-HBs ≥100 i.e./l pa je imelo
• redness or swelling where the injection was given 
• rdečina ali oteklina na mestu injiciranja, • povišana telesna temperatura,
It is used for patients with kidney problems: 
Podatki iz kliničnih študij Bolezni živčevja:
- Third injection 
NAPOLNJENA INJEKCIJSKA BRIZGA
GlaxoSmithKline (Malta) Ltd Tel: + 356 21 238131 
GlaxoSmithKline (Malta) Ltd
Very rare (these may occur with up to 1 in 10,000 doses of the vaccine) 
Zelo redki (pojavijo se lahko pri največ 1 na 10.000 odmerkov cepiva): • napadi krčev,
EU (MA) number Invented name 
EU (Številka dovoljenja za promet)
This means that Abseamed is highly similar to another biological medicine (the ‘reference medicine') that is already authorised in the EU. 
To pomeni, da je zelo podobno drugemu biološkemu zdravilu („referenčnemu zdravilu“), ki je že odobreno v EU.
Flu-like illness may occur especially at the start of treatment. 
Pojavijo se lahko gripi podobni simptomi, zlasti ob začetku zdravljenja.
Further information on Abseamed can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Nadaljnje informacije o zdravilu Abseamed so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Abseamed received a marketing authorisation valid throughout the EU on 28 August 2007. 
Za zdravilo Abseamed je bilo 28. avgusta 2007 izdano dovoljenje za promet, veljavno po vsej EU.
For these patients, the lowest dose that provides adequate control of symptoms should be used. 
Pri teh bolnikih je treba uporabiti najnižji odmerek, ki še zagotavlja ustrezni nadzor nad simptomi.
What measures are being taken to ensure the safe and effective use of Abseamed? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Abseamed?
The main measure of effectiveness was the change in the levels of haemoglobin between the start of the study and the evaluation period, between weeks 25 and 29. 
Glavno merilo učinkovitosti je bila razlika med ravnjo hemoglobina na začetku študije in ravnjo v obdobju ocenjevanja, ki je potekalo med 25. in 29. tednom.
An overview of Abseamed and why it is authorised in the EU 
Pregled zdravila Abseamed in zakaj je odobreno v EU
The iron levels of all patients should be checked to make sure that they are not too low, and iron supplements given if necessary. 
Pri vseh bolnikih je treba preveriti raven železa in s tem zagotoviti, da njihove vrednosti niso prenizke, ter po potrebi dajati dodatke, ki vsebujejo železo.
Abseamed is a medicine used for the following: 
Abseamed je zdravilo, ki se uporablja v naslednjih primerih:
What benefits of Abseamed have been shown in studies? 
Kakšne koristi zdravila Abseamed so se pokazale v študijah?
When Abseamed is used for autologous blood transfusion, the restrictions normally associated with this type of transfusion should be observed. 
Kadar se zdravilo Abseamed uporablja za avtologno transfuzijo krvi, je treba upoštevati omejitve, ki so običajno povezane s to vrsto transfuzije.
• patients with high blood pressure that is not controlled; 
• bolnikih z nenadzorovanim visokim krvnim tlakom;
Other information about Abseamed 
Druge informacije o zdravilu Abseamed
As for all medicines, data on the use of Abseamed are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Abseamed stalno spremljajo.
For patients with chronic kidney failure, myelodysplastic syndromes, or receiving chemotherapy, haemoglobin levels should remain within the recommended range (between 10 and 12 grams per decilitre in adults and between 9.5 and 11 g/dl in children). 
Pri bolnikih s kronično odpovedjo ledvic, mielodisplastičnimi sindromom ali tistih, ki prejemajo kemoterapijo, morajo ravni hemoglobina ostati v okviru priporočenih vrednosti (od 10 do 12 gramov na deciliter pri odraslih in od 9,5 do 11 gramov na deciliter pri otrocih).
Side effects reported with Abseamed are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Abseamed, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Why is Abseamed authorised in the EU? 
Zakaj je bilo zdravilo Abseamed odobreno v EU?
The most common side effects with Abseamed (which may affect more than 1 in 10 people) are nausea (feeling sick), diarrhoea, vomiting, fever and headache. 
Najpogostejši neželeni učinki zdravila Abseamed (ki se lahko pojavijo pri več kot 1 bolniku od 10) so navzeja (slabost), driska, bruhanje, povišana telesna temperatura in glavobol.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Abseamed have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Abseamed upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
What are the risks associated with Abseamed? 
Kakšna tveganja so povezana z zdravilom Abseamed?
Epoetin alfa is also used before surgery to increase the number of red blood cells and help minimise the consequences of blood loss. 
Epoetin alfa se uporablja tudi pred kirurškimi posegi za povečanje števila rdečih krvnih celic in kot pomoč pri zmanjšanju posledic izgube krvi.
It is used in patients with normal blood iron levels who could experience complications from a blood transfusion, if they do not donate their own blood before surgery and are expected to lose 900 to 1,800 ml of blood; 
Zdravilo se uporablja pri bolnikih z normalnimi ravnmi železa, pri katerih lahko pride do zapletov pri transfuziji krvi, če pred kirurškim posegom ne darujejo lastne krvi, pričakovane izgube pa znašajo od 900 ml do 1 800 ml;
• patients undergoing surgery who cannot receive medicines for the prevention of blood clots; 
• bolnikih, pri katerih bo izveden kirurški poseg in ne morejo prejemati zdravil za preprečevanje nastajanja krvnih strdkov;
For more information about using Abseamed, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Abseamed glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
• patients about to undergo major orthopaedic surgery who have severe cardiovascular (heart and blood vessel) problems including a recent heart attack or stroke. 
• bolnikih, ki so tik pred zahtevnejšim ortopedskim kirurškim posegom in imajo resne kardiovaskularne (srčno-žilne) težave, vključno z nedavnim srčnim napadom ali možgansko kapjo.
What is Abseamed and what is it used for? 
Kaj je zdravilo Abseamed in za kaj se uporablja?
In these cases, epoetin alfa is used to increase red blood cell counts. 
V teh primerih se za povečanje števila rdečih krvnih celic uporablja epoetin alfa.
The dose, the frequency of injection and how long it is used for also depend on why Abseamed is being used and on the patient's bodyweight, and are adjusted according to how well the medicine is working. 
Odmerek, pogostost injiciranja in trajanje uporabe zdravila Abseamed so odvisni od razloga za njegovo uporabo in bolnikove telesne mase ter jih je treba prilagoditi glede na učinkovitost delovanja zdravila.
Abseamed must not be used in the following groups: 
Zdravilo se ne sme uporabljati pri naslednjih skupinah bolnikov:
• to treat anaemia in adults receiving chemotherapy for certain types of cancer and to reduce the need for blood transfusions; 
• za zdravljenje anemije pri odraslih, pri katerih s kemoterapijo zdravijo določene vrste raka, in za zmanjšanje potrebe po transfuziji krvi;
• to treat anaemia (low red blood cell counts) that is causing symptoms in patients with chronic kidney failure (long-term, progressive decrease in the ability of the kidneys to work properly) or other kidney problems; 
• za zdravljenje anemije (nizkega števila rdečih krvnih celic), ki povzroča simptome pri bolnikih s kronično odpovedjo ledvic (dolgotrajnim in napredujočim upadanjem sposobnosti pravilnega delovanja ledvic) ali drugimi težavami z ledvicami;
In patients receiving chemotherapy or with kidney problems, anaemia can be caused by a lack of erythropoietin, or by the body not responding well enough to natural erythropoietin. 
Pri bolnikih, ki prejemajo kemoterapijo, ali tistih z ledvičnimi težavami lahko anemijo povzroči pomanjkanje eritropoetina ali nezadostna odzivnost telesa na naravno prisotni eritropoetin.
The active substance in Abseamed, epoetin alfa, is a copy of a hormone called erythropoietin, and works in exactly the same way as the natural hormone to stimulate the production of red blood cells in the bone marrow. 
Učinkovina v zdravilu Abseamed, epoetin alfa, je kopija hormona eritropoetina in deluje popolnoma enako kot naravni hormon pri spodbujanju nastajanja rdečih krvnih celic v kostnem mozgu.
Abseamed contains the active substance epoetin alfa and is a ‘biosimilar medicine'. 
Zdravilo Abseamed vsebuje učinkovino epoetin alfa in je „podobno biološko zdravilo“.
• to increase the amount of blood that can be taken in adult patients with moderate anaemia and normal blood iron levels who are going to have an operation and donate their own blood before surgery (autologous blood transfusion); 
• za povečanje količine krvi, ki jo je mogoče odvzeti odraslim bolnikom z zmerno anemijo in normalno ravnjo železa v krvi, ki bodo imeli kirurški poseg in pred tem darujejo lastno kri (avtologna transfuzija krvi);
Abseamed can only be obtained with a prescription and treatment must be started under the supervision of a doctor who has experience in the management of patients with the conditions that Abseamed is used for. 
Predpisovanje in izdaja zdravila Abseamed je le na recept, zdravljenje z njim pa se lahko uvede le pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem bolnikov z boleznimi, za katere se to zdravilo uporablja.
Because Abseamed is a biosimilar medicine, the studies on effectiveness and safety of epoetin alfa carried out with Eprex/Erypo do not all need to be repeated for Abseamed. 
Ker je zdravilo Abseamed podobno biološko zdravilo, študij o učinkovitosti in varnosti učinkovine epoetin alfa, ki so že bile izvedene z zdravilom Eprex/Erypo, za zdravilo Abseamed ni treba ponavljati.
Abseamed is used when patients are at low or intermediate risk of developing acute myeloid leukaemia and have low levels of the natural hormone erythropoietin. 
Zdravilo Abseamed se uporablja pri bolnikih, pri katerih obstaja majhno ali srednje tveganje za pojav akutne mieloične levkemije in ki imajo nizke ravni naravnega hormona eritropoetina.
The reference medicine for Abseamed is Eprex/Erypo. 
Referenčno zdravilo za zdravilo Abseamed je zdravilo Eprex/Erypo.
All of the patients had been receiving Eprex/Erypo injected into a vein for at least 8 weeks before they were either switched to Abseamed or remained on Eprex/Erypo. 
Vsem bolnikom so zdravilo Eprex/Erypo najmanj osem tednov injicirali v veno, preden so bodisi začeli prejemati zdravilo Abseamed bodisi so še naprej prejemali zdravilo Eprex/Erypo.
Abseamed is available in pre-filled syringes of various strengths and is given as an injection into a vein or as an injection under the skin, depending on the condition for which the patient is being treated. 
Zdravilo Abseamed je na voljo v napolnjenih injekcijskih brizgah različnih jakosti in se daje z injiciranjem v veno ali podkožje, kar je odvisno od bolezenskega stanja bolnika, ki se zdravi.
• to treat anaemia in adults with myelodysplastic syndromes (conditions in which the production of healthy blood cells is defective). 
• za zdravljenje anemije pri odraslih z mielodisplastičnimi sindromi (obolenji, pri katerih je okvarjeno nastajanje zdravih krvnih celic).
The injection under the skin may be given by the patient or their carer if they have been appropriately trained. 
Bolnik si zdravilo lahko v podkožje injicira sam ali mu ga injicira negovalec, če sta bila za to ustrezno usposobljena.
Therefore the Agency's view was that, as for Eprex/Erypo, the benefit of Abseamed outweighs the identified risk and it can be authorised. 
Agencija je zato menila, da koristi zdravila Abseamed enako kot pri zdravilu Eprex/Erypo odtehtajo znana tveganja in da se zdravilo lahko odobri.
The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Abseamed has a highly similar structure, purity and biological activity to Eprex/Erypo and is distributed in the body in the same way. 
Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU glede podobnih bioloških zdravil dokazano, da je zdravilo Abseamed po zgradbi, čistosti in biološkem delovanju primerljivo zdravilu Eprex/Erypo in da se po telesu enako prenaša.
Patients switching to Abseamed maintained haemoglobin levels to the same extent as those continuing with Eprex/Erypo. 
Bolniki, ki so prešli na jemanje zdravila Abseamed, so ohranili vrednost hemoglobina na enaki ravni kot bolniki, ki so nadaljevali zdravljenje z zdravilom Eprex/Erypo.
How is Abseamed used? 
Kako se zdravilo Abseamed uporablja?
Laboratory studies comparing Abseamed with the reference medicine Eprex/Erypo have shown that the active substance in Abseamed is highly similar to that in Eprex/Erypo in terms of structure, purity and biological activity. 
Laboratorijske študije, v katerih so zdravilo Abseamed primerjali z referenčnim zdravilom Eprex/Erypo, so pokazale, da je učinkovina v zdravilu Abseamed po zgradbi, čistosti in biološkem delovanju zelo podobna učinkovini v zdravilu Eprex/Erypo.
• to reduce the need for blood transfusions in adults with moderate anaemia who are about to undergo major orthopaedic (bone) surgery, such as hip surgery. 
• za zmanjšanje potrebe po transfuziji krvi pri odraslih z blago obliko anemije pred zahtevnejšim ortopedskim kirurškim posegom (na kosteh), na primer operacijo kolkov.
• patients who have developed pure red cell aplasia (reduced or stopped red blood cell production) 
(zmanjšano ali zaustavljeno tvorjenje rdečih krvnih celic);
For the full list of side effects of Abseamed, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Abseamed, glejte navodilo za uporabo.
In addition, studies have shown that the effects of the medicine are equivalent to those of Eprex/Erypo in increasing and maintaining blood cell counts in patients with chronic kidney failure or undergoing chemotherapy. 
Poleg tega so študije pokazale, da so učinki tega zdravila pri zviševanju in ohranjanju števila rdečih krvnih celic pri bolnikih s kronično odpovedjo ledvic ali tistih, ki prejemajo kemoterapijo, enakovredni učinkom zdravila Eprex/Erypo.
Abseamed, injected into a vein, was compared with the reference medicine in one main study involving 479 patients with anaemia caused by kidney problems. 
V eni glavni študiji, ki je vključevala 479 bolnikov z anemijo, povezano z obolenjem ledvic, so zdravilo Abseamed, injicirano v veno, primerjali z referenčnim zdravilom.
Studies have also shown that giving Abseamed produces similar levels of the active substance in the body to giving Eprex/Erypo. 
Študije so pokazale tudi, da zdravilo Abseamed vzpostavi podobne ravni učinkovine v telesu kot zdravilo Eprex/Erypo.
A further study showed that Abseamed was safe and effective when given under the skin in 416 patients with chronic kidney failure. 
V dodatni študiji so pri 416 bolnikih s kronično odpovedjo ledvic dokazali, da je zdravilo Abseamed pri injiciranju v podkožje varno in učinkovito.
In addition, Abseamed was shown to be as effective as Eprex/Erypo at increasing and maintaining red blood cell counts in several studies. 
Poleg tega so v več študijah dokazali, da je zdravilo Abseamed pri zviševanju in ohranjanju števila rdečih krvnih celic enako učinkovito kot zdravilo Eprex/Erypo.
Another study showed that Abseamed injected under the skin was as effective in maintaining haemoglobin levels as Eprex/Erypo in 114 cancer patients who were receiving chemotherapy. 
Druga študija pri 114 bolnikih z rakavimi obolenji, ki so prejemali kemoterapijo, je pokazala, da je bilo zdravilo Abseamed, injicirano v podkožje, enako učinkovito pri ohranjanju ravni hemoglobina kot zdravilo Eprex/Erypo.
How does Abseamed work? 
Kako zdravilo Abseamed deluje?
Vial (type I glass) closed with a halogenobutyl rubber stopper and aluminium cap 
Intramuskularno Viala (steklo tipa I) zaprta z zamaškom iz halogenobutilne gume in aluminijasto zaporko
--1 Equine influenza virus strains: A/equine-2/South Africa/4/03 strain 
--1 Seva virusa influence konj: A/konjski-2/Južna Afrika/4/03 50 AU/ml A/konjski-2/ Newmarket/2/93 50 AU/ml Toksoid tetanusa
40 Lf/ml 
40 Lf2
1 dose 10 glass vials 
1 odmerek 10 steklenih vial Nič dni
Tetanus toxoid 
Karenca
List of the names, pharmaceutical form, strength of the medicinal product, route of administration, applicant / marketing authorisation holder in the Member States 
Seznam imen, farmacevtske oblike, jakosti zdravila, načina uporabe, predlagatelja, imetnika dovoljenja za promet z zdravilom v državah članicah
The application was submitted to Ireland as reference Member State and Austria, Bulgaria, Denmark, Spain, Finland, France, Hungary, the Netherlands, Poland, Portugal, Romania, Sweden, Slovenia as concerned Member States, as well as Iceland and Norway. 
Vloga je bila predložena Irski kot referenčni državi članici in Avstriji, Bolgariji, Danski, Španiji, Finski, Franciji, Madžarski, Nizozemski, Poljski, Portugalski, Romuniji, Švedski ter Sloveniji kot zadevnim državam članicam ter Islandiji in Norveški.
The final opinion was converted into a Decision by the European Commission on 25 May 2012. 
Končno mnenje je bilo spremenjeno v Odločbo Evropske komisije dne 25. maja 2012.
The applicant, Pfizer Limited, has submitted an application for a decentralised procedure for the above mentioned veterinary medicinal product in the framework of Article 32 of Directive 2001/82/EC, as amended. 
Predlagatelj, družba Pfizer Limited, je predložil vlogo za začetek decentraliziranega postopka za zgoraj omenjeno zdravilo za uporabo v veterinarski medicini v okviru člena 32 Direktive 2001/82/ES, kakor je bila spremenjena.
Doramectin is a macrocyclic lactone and is closely related to ivermectin. 
Doramektin je makrociklični lakton in je zelo soroden ivermektinu.
Potential serious risks were identified during the decentralised procedure by two concerned Member States regarding the environmental risk assessment (the Netherlands and France). 
V okviru decentraliziranega postopka sta dve zadevni državi članici (Nizozemska in Francija) opredelili morebitna resna tveganja glede ocene tveganja za okolje.
Prontax 5 mg/ml pour-on solution for cattle (and associated names) contains doramectin. 
Zdravilo Prontax 5 mg/ml kožni poliv, raztopina za govedo (in povezana imena) vsebuje doramektin.
Based on evaluation of the currently available data, the CVMP considered that the benefit-risk profile of Prontax 5 mg/ml pour-on solution for cattle and associated names is deemed to be positive provided that the recommended risk mitigation measures are added to the product information regarding risk to aquatic organisms and dung fauna. 
Na podlagi ocene trenutno razpoložljivih podatkov je odbor CVMP presodil, da razmerje med koristmi in tveganji za zdravilo Prontax 5 mg/ml kožni poliv, raztopina za govedo, in povezana imena, velja za pozitivno, če so informacijam o zdravilu dodani priporočeni ukrepi za zmanjšanje tveganja v zvezi s
referral for Prontax 5 mg/ml pour-on solution for cattle and associated names 
za zdravilo Prontax 5 mg/ml kožni poliv, raztopina za govedo, in povezana imena
Opinion following an Article 33(4)F F referral for Prontax 5 mg/ml pour-on solution for cattle and associated names 
Mnenje v zvezi z napotitvijo v skladu s členom 33(4)F F za zdravilo Prontax 5 mg/ml kožni poliv, raztopina za govedo, in povezana imena EMA/421650/2012
recommending the granting of a Marketing Authorisation for Prontax 5 mg/ml pour-on solution for cattle and associated names. 
Odbor CVMP je zato 8. februarja2012 sprejel pozitivno mnenje, v katerem priporoča odobritev dovoljenja za promet z zdravilom Prontax 5 mg/ml kožni poliv, raztopina za govedo, in povezana imena.
The active substance in Pioglitazone Teva Generics, pioglitazone, makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces. 
Zdravilna učinkovina zdravila Pioglitazone Teva Generics, pioglitazon, poveča občutljivost celic (maščevja, mišic in jeter) za insulin, kar pomeni, da telo bolje izrablja insulin, ki ga proizvaja.
This means that Pioglitazone Teva Generics is similar to a ‘reference medicine' already authorised in the European Union (EU) called Actos. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Actos.
Pioglitazone Teva Generics was to be used to treat type 2 diabetes in adults, particularly those who are overweight. 
Zdravilo Pioglitazone Teva Generics naj bi se uporabljalo za zdravljenje sladkorne bolezni tipa 2 pri odraslih, zlasti tistih s prekomerno telesno maso.
The CHMP concluded that, in accordance with EU requirements, Pioglitazone Teva Generics had been shown to have comparable quality and to be bioequivalent to Actos. 
CHMP je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Pioglitazone Teva Generics primerljivo raven kakovosti kot zdravilo Actos ter da mu je biološko enakovredno.
On 26 January 2012, TEVA Generics B.V. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Pioglitazone Teva Generics, for the treatment of type 2 diabetes. 
je dne 26. januarja 2012 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za pridobitev dovoljenja za promet z zdravilom Pioglitazone Teva Generics, namenjenim zdravljenju sladkorne bolezni tipa 2.
Because Pioglitazone Teva Generics is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Actos. 
Ker je zdravilo Pioglitazone Teva Generics generično zdravilo, so bile študije pri bolnikih omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Actos.
Pioglitazone Teva Generics was developed as a ‘generic medicine'. 
Zdravilo Pioglitazone Teva Generics je bilo razvito kot „generično zdravilo“.